Select Your GLP-1 Drug
Choose your prescribed medication to see customized guidance
Ozempic
Type 2 Diabetes + Weight Loss
$935/month average
Semaglutide 0.25-2.0mg weekly injection
Wegovy
Weight Loss (Obesity)
$1,349/month average
Semaglutide 2.4mg weekly injection
Mounjaro
Type 2 Diabetes
$1,023/month average
Tirzepatide 2.5-15mg weekly injection
Zepbound
Weight Loss (Obesity)
$1,059/month average
Tirzepatide 2.5-15mg weekly injection
🏢 What Insurance Companies Do
- Force you through 6-18 months of "step therapy"
- Require you to "fail" cheaper drugs first
- Bury denial reasons in confusing letters
- Hope you give up and pay $1,000+/month
- Use algorithms instead of doctors
🛡️ What We Do
- Show you exactly how to skip step therapy
- Explain why YOUR situation qualifies
- Provide proven templates that work
- Help you get $25/month coverage instead
- Put your doctor's judgment first
🤝 Why Is This Free?
We're building proof that fighting back works. In exchange for free help, we just ask: tell us if it worked. Your anonymous outcome helps us improve and shows others they can win too. That's the deal.
Why Insurance Denies GLP-1 Drugs (Step Therapy)
The Insurance Profit Motive
Insurance companies use "step therapy" (also called "fail first" policies) to force you to try cheaper alternatives before approving expensive GLP-1 drugs. Here's what they require:
$4-$30/month generic diabetes drug. Must "fail" for 3-6 months.
$10-$50/month generics. Another 3-6 month "trial period."
$200-$500/month. Some plans require this step too.
After 6-18 months of "failing" cheaper drugs, you MAY get approved.
5 Proven Step Therapy Override Strategies That Work
Strategy #1: Medical Necessity Letter from Doctor 🔥 Most Effective
How it works: Your doctor writes a detailed letter explaining why you need THIS specific drug NOW (not in 6-18 months).
Key elements your doctor should include:
- Clinical urgency: A1C above 9%, diabetic complications present, rapid weight gain
- Prior failures: Already tried metformin/other generics (even if informally)
- Contraindications: Side effects from cheaper alternatives (nausea, hypoglycemia, GI issues)
- Evidence base: Cite FDA approval, clinical trials showing GLP-1 superiority
- Timeline urgency: Risk of hospitalization, irreversible complications without immediate treatment
Timeline: 5-14 days for review. Get doctor letter template →
Strategy #2: Document Prior Medication Failures 💪 Highly Effective
How it works: Prove you've ALREADY tried (and failed) the cheaper drugs insurance wants you to take.
What counts as "failure":
- Lack of efficacy: Metformin didn't lower A1C after 3+ months
- Intolerable side effects: Severe GI distress, hypoglycemia, allergic reactions
- Medical contraindications: Kidney disease (can't take metformin), heart failure
- Informal trials: Even samples or short trials count - get doctor to document
Evidence needed: Prescription records, doctor notes, pharmacy records showing prior fills.
Strategy #3: Emergency Appeal (Diabetes Complications) ⚡ Fast Track
How it works: If you have diabetic complications (neuropathy, retinopathy, nephropathy), you can request URGENT review (72 hours instead of 30 days).
Qualifying complications:
- A1C ≥9% (severe uncontrolled diabetes)
- Diabetic neuropathy (nerve damage, pain, numbness)
- Diabetic retinopathy (vision changes, eye damage)
- Diabetic nephropathy (kidney damage, protein in urine)
- History of diabetic ketoacidosis (DKA)
- Cardiovascular disease with diabetes
Why this works: Insurance MUST respond to urgent appeals within 72 hours. They know delaying treatment for serious complications creates liability.
Strategy #4: State Mandate Research 📜 Legal Leverage
How it works: Some states require insurance to cover GLP-1 drugs for diabetes or obesity. If your state has a mandate, cite it in your appeal.
States with GLP-1 coverage mandates:
- California: Must cover FDA-approved obesity treatments (including GLP-1s) for BMI ≥30
- New York: Diabetes drug coverage required without step therapy for A1C >8%
- Illinois: Anti-obesity medication coverage mandate (2024)
- Massachusetts: Comprehensive diabetes coverage law
Strategy #5: Peer-to-Peer Review Request 🩺 Doctor-to-Doctor
How it works: Request that a DOCTOR at the insurance company (not a claims clerk) review your case and speak directly with your prescribing doctor.
Why this works: Most denials are made by non-clinical staff using outdated algorithms. When a medical director reviews your case, they often approve based on clinical evidence.
How to request: Call insurance and say: "I request a peer-to-peer review by a board-certified endocrinologist. My doctor is available [provide availability]."
GLP-1 Drug Comparison: Coverage & Costs
| Drug | FDA Use | Avg Cost | Coverage Rate | Step Therapy? |
|---|---|---|---|---|
| Ozempic | Type 2 Diabetes (+ off-label weight loss) | $935/month | 72% (diabetes) 31% (weight loss) |
Yes (85% of plans) |
| Wegovy | Obesity/Weight Management | $1,349/month | 28% (higher denial rate) | Yes (91% of plans) |
| Mounjaro | Type 2 Diabetes | $1,023/month | 68% (diabetes only) | Yes (82% of plans) |
| Zepbound | Obesity/Weight Management | $1,059/month | 24% (newer drug, higher denials) | Yes (93% of plans) |
Appeal Timeline: How Long Will This Take?
Standard Appeal (No Complications)
- Day 1-3: Submit appeal with doctor letter + prior failure documentation
- Day 4-30: Insurance review period (legally required to respond within 30 days)
- Day 15-20: Often hear back within 2-3 weeks for strong appeals
- If denied: Request external review (60-90 days) - your best chance at independent review
🚨 Urgent Appeal (Diabetes Complications)
- Day 1: Submit urgent appeal citing medical complications
- Day 2-3: Insurance MUST respond within 72 hours
- If denied: External urgent review within 48 hours
Qualifying for urgent review: A1C ≥9%, existing complications (neuropathy, retinopathy, nephropathy), recent hospitalization.
Real Success Stories: Appeals That Won
Jennifer M. - Wegovy Approved After Initial Denial
Situation: BMI 34, tried multiple diets, insurance denied Wegovy citing "cosmetic use."
Strategy: Doctor letter emphasizing obesity-related health conditions (hypertension, prediabetes, sleep apnea). Cited FDA approval for obesity treatment and risk of diabetes progression.
Result: Approved in 18 days. Lost 47 lbs in 6 months, blood pressure normalized.
Key factor: Documented comorbidities (hypertension, prediabetes) made it medical necessity, not cosmetic.
Michael T. - Ozempic Urgent Appeal (Diabetes Complications)
Situation: Type 2 diabetes, A1C 9.8%, early neuropathy symptoms. Insurance required 6-month metformin trial first.
Strategy: Urgent appeal citing A1C >9% and diabetic neuropathy. Doctor documented metformin trial 2 years prior with inadequate control.
Result: Approved in 3 days (urgent 72-hour review). A1C dropped to 6.9% in 4 months.
Key factor: Emergency criteria (complications + A1C >9%) triggered immediate review.
Sarah L. - Mounjaro Step Therapy Override
Situation: Type 2 diabetes, severe GI side effects from metformin. Insurance denied Mounjaro, required sulfonylurea trial next.
Strategy: Documented metformin intolerance (nausea, diarrhea forced discontinuation). Peer-to-peer review where doctor explained GLP-1 safety advantage vs sulfonylureas (no hypoglycemia risk).
Result: Approved after peer-to-peer call. Doctor emphasized patient safety concerns and clinical trial data.
Key factor: Medical director agreed patient safety warranted skipping step therapy.
David K. - State Mandate Override (California)
Situation: BMI 38, insurance denied Wegovy as "not medically necessary." California resident.
Strategy: Cited California law requiring obesity treatment coverage for BMI ≥30. Included state insurance commissioner contact info in appeal.
Result: Approved in 12 days. Insurance reversed denial citing state mandate compliance.
Key factor: State law trumped insurance policy. Mentioning commissioner complaint triggered approval.
They Made It Hard. We Made It Easy.
Upload your denial letter and let our AI team write your appeal in minutes.
Start My GLP-1 Appeal Now →Or download proven templates that won $40,000+ in GLP-1 drug approvals:
Frequently Asked Questions
Typically 6-18 months. Most insurance plans require:
- 3-6 months trial of metformin (first-line)
- 3-6 months trial of sulfonylureas or DPP-4 inhibitors (second-line)
- Documented "failure" of each (A1C not reaching goal despite compliance)
This delay can worsen diabetic complications and prevent critical weight loss. You can skip this with a successful appeal.
It's harder but possible. Ozempic is FDA-approved only for type 2 diabetes, so weight loss is "off-label." Your best strategies:
- Document prediabetes: A1C 5.7-6.4% or fasting glucose 100-125 mg/dL makes it preventive diabetes care
- Emphasize comorbidities: Obesity + hypertension, sleep apnea, fatty liver disease = medical necessity
- State mandates: California, Illinois require obesity medication coverage regardless of diabetes status
- Consider Wegovy instead: Same drug (semaglutide) but FDA-approved for obesity, slightly higher coverage rate for weight loss
Coverage rate: 31% for weight loss vs 72% for diabetes. But appeals can overcome initial denials.
This is GOLD for your appeal! Insurance step therapy requires you to "fail" cheaper drugs, but it doesn't specify WHEN. If you:
- Took metformin for PCOS, prediabetes, or previous diabetes diagnosis
- Discontinued due to side effects (GI issues, lactic acidosis risk)
- Had inadequate efficacy (didn't reach treatment goals)
Have your doctor document this in your medical necessity letter. Even a 2-week trial from 5 years ago counts. Request your pharmacy records to prove it.
Pro tip: "Failure" includes intolerance (side effects), not just lack of efficacy.
You qualify for urgent (expedited) appeal if denying treatment could "seriously jeopardize your life or health." For GLP-1 drugs, this includes:
- Uncontrolled diabetes: A1C ≥9% despite current medications
- Diabetic complications: Neuropathy, retinopathy, nephropathy, cardiovascular disease
- Recent hospitalization: DKA, hyperglycemic crisis, obesity-related ER visit
- Rapid progression: A1C rising >1 point in 3 months despite treatment
Timeline: Insurance MUST respond within 72 hours (vs 30 days for standard). External urgent review is 48 hours.
If you qualify, write "URGENT APPEAL - EXPEDITED REVIEW REQUESTED" at the top of your appeal letter and state why delay threatens your health.
Yes, but it's very expensive:
- Ozempic: $935/month ($11,220/year)
- Wegovy: $1,349/month ($16,188/year)
- Mounjaro: $1,023/month ($12,276/year)
- Zepbound: $1,059/month ($12,708/year)
Manufacturer savings cards: Eli Lilly and Novo Nordisk offer copay cards that reduce cost to $25-$150/month IF you have commercial insurance (even if denied). These DON'T work with Medicare/Medicaid.
Better strategy: Appeal for coverage ($25-$75/month copay) while using manufacturer card as bridge.
They're the SAME medication (semaglutide), just different FDA approvals and doses:
- Ozempic: Approved for type 2 diabetes. Doses: 0.25mg, 0.5mg, 1mg, 2mg weekly
- Wegovy: Approved for obesity/weight management. Dose: 2.4mg weekly (higher dose)
Insurance coverage: Ozempic has better coverage for diabetes (72%) vs Wegovy for weight loss (28%), but Wegovy is explicitly approved for obesity.
Strategy: If you have type 2 diabetes OR prediabetes, request Ozempic (better coverage). If BMI ≥30 with no diabetes, request Wegovy (FDA-approved for your condition).
No. Insurance does not cover compounded GLP-1 drugs because they're not FDA-approved.
Compounded semaglutide from wellness clinics ($200-$400/month) is cheaper than brand-name Ozempic/Wegovy, but:
- Not FDA-approved (quality/potency not guaranteed)
- Insurance won't cover
- HSA/FSA usually won't reimburse
- No manufacturer savings cards
Better approach: Appeal for brand-name coverage ($25-$75/month copay with insurance) rather than paying $200-$400/month for compounded.
You have two powerful next steps:
1. External Review (Independent Medical Review)
- Request within 180 days of denial
- Independent doctor reviews your case (not employed by your insurance)
- FREE in most states
- Your odds improve dramatically with strong medical evidence
- Timeline: 60-90 days (or 48 hours if urgent)
2. State Insurance Commissioner Complaint
- File complaint if insurance violated state coverage mandates
- Especially effective in CA, NY, IL, MA with GLP-1 coverage laws
- Insurance must respond to commissioner inquiries
- Often leads to reversal to avoid regulatory scrutiny
Don't give up after first denial. External review has much higher approval rate.
For diabetes: Yes. Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes treatment.
For weight loss: No. Federal law prohibits Medicare from covering weight loss drugs, including Wegovy and Zepbound.
The loophole:
- If you have type 2 diabetes + need to lose weight, get Ozempic or Mounjaro (approved for diabetes, weight loss is "side effect")
- Medicare Advantage plans may have different rules - some cover weight loss drugs
- Recent proposal to expand Medicare coverage for obesity drugs - may change in 2024-2025
Manufacturer cards DON'T work with Medicare (federal law prohibits), but Medicare copays are typically $35-$75/month.
Yes, and this might even help your appeal. Mounjaro (tirzepatide) is a newer GLP-1 + GIP dual agonist with stronger weight loss results in trials.
Reasons to switch (and how to appeal):
- Better efficacy: SURMOUNT trials showed 15-21% weight loss vs 10-15% with semaglutide
- Better A1C reduction: Average 2.0-2.5% A1C drop vs 1.5-2.0% with Ozempic
- Ozempic plateau: If you've hit plateau after 6+ months on Ozempic, switching to Mounjaro is medically justified
Appeal strategy: Have doctor document Ozempic trial results (weight loss achieved but plateaued, or A1C improved but not to goal), then request Mounjaro as next-line therapy with superior clinical data.
Clinical trial results (over 68 weeks):
- Wegovy (semaglutide 2.4mg): Average 15% body weight loss (33 lbs for 220-lb person)
- Ozempic (semaglutide up to 2mg): Average 10-12% body weight loss (22-26 lbs for 220-lb person)
- Mounjaro (tirzepatide 10-15mg): Average 15-21% body weight loss (33-46 lbs for 220-lb person)
- Zepbound (tirzepatide 10-15mg): Average 18-21% body weight loss (same as Mounjaro)
Real-world variability: Results range from 5% to 25%+ weight loss depending on diet, exercise, dose, and individual response.
For insurance appeal: Cite FDA trial data and emphasize that even 5-10% weight loss significantly improves diabetes control, blood pressure, and cardiovascular risk.
FDA approval criteria (what doctors can prescribe):
- BMI ≥30 (obesity), OR
- BMI ≥27 (overweight) with at least one weight-related comorbidity:
- Type 2 diabetes or prediabetes
- Hypertension (high blood pressure)
- Dyslipidemia (high cholesterol)
- Obstructive sleep apnea
- Cardiovascular disease
Insurance coverage criteria (stricter): Many insurers require BMI ≥35 or BMI ≥30 with comorbidity. Check your plan's medical policy.
Calculate your BMI above to see if you qualify and what strategy to use in your appeal.
Yes, but only with commercial insurance.
Ozempic/Wegovy Savings Card (Novo Nordisk):
- Reduces copay to as low as $25/month
- Requires commercial insurance (even if drug is denied)
- NOT valid with Medicare, Medicaid, or if uninsured
- Must reapply every 12 months
Mounjaro/Zepbound Savings Card (Eli Lilly):
- Reduces copay to as low as $25/month
- Same restrictions (commercial insurance only)
- Some patients get up to $150/month discount
Strategy: Use savings card while appealing denial. If appeal succeeds, you'll have insurance coverage + low copay permanently. If appeal fails, card keeps cost manageable while you pursue external review.
Most plans cover ongoing use IF you meet criteria:
For diabetes (Ozempic, Mounjaro):
- Coverage continues as long as A1C remains elevated (typically >7%)
- Some plans require periodic re-authorization (every 6-12 months)
- Must show ongoing benefit (A1C control, weight management)
For weight loss (Wegovy, Zepbound):
- Many plans require you to lose ≥5% body weight in first 3-6 months to continue coverage
- Must maintain weight loss to keep approval
- Some plans limit coverage to 12-24 months
Lifetime coverage: If you have type 2 diabetes, coverage is typically ongoing. For weight loss only, expect periodic reviews to prove continued medical necessity.
Weight regain is common: Studies show most patients regain 2/3 of lost weight within 12 months of stopping.
This is why insurance coverage matters: GLP-1 drugs are designed for long-term use (like blood pressure medication), not short-term treatment. You'll likely need ongoing medication to maintain weight loss and diabetes control.
For your appeal: Emphasize that this is chronic disease management, not cosmetic treatment. Just like you wouldn't stop taking blood pressure medication after 6 months, obesity and diabetes require ongoing treatment.
A1C effects: Diabetes control typically reverts within 3-6 months of stopping unless lifestyle changes are maintained.